SEC Form 4 · accession 0001572426-17-000006
Nexvet Biopharma plc · NVET
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph S McCracken
Director
Period of report
Dec 31, 2016
Accepted (ET)
Jan 3, 2017 · 7:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001618561
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Dec 31, 2016 | M | 500 | $0.125 | A | 11,800 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Share UnitsF1 | $0.125 | Dec 31, 2016 | M | 500 | D | — | Jul 1, 2019 | Ordinary Shares | 500 | 1,000 | D |
Explanation of responses
- F1500 of the Restricted Share Units vested and became convertible on 12/31/16, and 500 Restricted Share Units shall vest and become convertible on each of 3/31/17 and 6/30/17, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.